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Abstract The sexual hormone of S. cerevisiae, a-mating factor 
(a-MF, WHWLQLKPGQPMY) has structural homology with 
mammalian iuteinizing hormone releasing hormone (LHRH, 
pEHWSYGLRPG-NH2) and has been shown to exhibit LHRH 
activity [Loumaye et al. (1982) Science 218, 1323-1325]. We 
have tested whether LHRH has a-MF activity in yeast and found 
that it does not. We therefore synthesized a series of hybrid 
peptides of a-MF and LHRH to study the structural features 
which determine a-MF and LHRH activities. A hybrid peptide 
consisting of the LHRH sequence with the C-terminal tetrapep- 
tide (QPMY) of a-MF did not exhibit a-MF activity. Thus, the 
lack of a-MF activity of LHRH is not due solely to the absence 
of the C-terminal residues. Substitution of Lys in a-MF with 
Arg, as is found in LHRH, did not affect the a-MF activity, nor 
did an additional substitution of Trp 1 with pGlu. However, the C- 
terminal four amino acids of a-MF were necessary for a-MF 
activity. Our results indicate that insertion of a Ser residue in 
position 4 as found in LHRH abolishes a-MF activity. These 
results suggest hat, in addition to an intact C-terminus, correct 
spacing of the N-terminal His 2 and the C-terminus is required for 
a-MF activity. The hybrid peptides all exhibited less LHRH 
activity than either LHRH or a-MF. These structure-function 
studies indicate that the structural homology between these two 
reproductive hormones may not reflect an evolutionary relation- 
ship between them. 
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1. Introduction 
Comparative studies of signal transduction i  mammalian 
cells and yeasts have revealed a significant structural and 
functional conservation of the components involved. The uni- 
cellular yeasts S. pombe and S. cerevisiae are therefore useful 
models for studying several cellular mechanisms including 
growth control and differentiation [1]. The budding yeast S. 
cerevisiae xists in one of two mating types, a and a, which 
can mate with each other [2]. During the mating process the 
cells communicate by excreting diffusible pheromones, a- 
mating factor (a-MF) or a-mating factor. The cells respond 
to the mating factors by elongating towards the pheromone 
source, by altered patterns of gene transcription and by G1 
arrest of cell division. The mating factors are thus negative 
growth factors in yeast. Since many cellular signaling systems 
in mammals and yeasts are homologous the latter are useful 
for elucidating specific parts of these systems. As shown in 
Table 1, S. cerevisiae a-MF is homologous to mammalian 
LHRH and has been found to exhibit some LHRH activity 
[3]. Since the receptors for these hormones both belong to the 
seven transmembrane family of G protein-coupled receptors 
[4-6], structure/function studies of the hormones might yield 
information about receptor binding and activation, which 
could be important in the design of LHRH agonists and an- 
tagonists. Apart from its function in LH release, LHRH has 
been found to have growth inhibitory effects on several cell 
lines [7-10] and thus shares with a -MF  the property of 
growth inhibition/differentiation [11-14]. We have explored 
the structural similarity of LHRH and a -MF in more detail 
by testing LHRH for a -MF  activity and by synthesizing hy- 
brids of LHRH and a-MF,  and testing the hybrids for a -MF  
activity and for binding to a mammalian LHRH receptor. 
2. Materials and methods 
All chemicals were of analytical grade or higher quality. 
Peptides, synthesized by the solid-phase method, LHRH, and bu- 
serelin ([D-Ser6(t-Bu),des-Glyl°,ProgNHEt]-LHRH) were from Pep- 
tech Europe (Copenhagen, Denmark). c~-mating factor was from Sig- 
ma (St. Louis, USA). 
S. cerevisiae strain MT502 (genotype: Mata sst2- leu2-3, 112 met1 
his3 and~or 6 can1) was kindly provided by Egel-Mitani et al. [15]. 
Amino acid analysis was performed as described by Barkholt and 
Jensen [16]. 
Mass spectrometry was carried out on a Bio-Ion model 20 mass 
spectrometer operated at 13 kV accelerating voltage. Samples were 
applied to nitrocellulose-coated targets and air-dried before analysis. 
Assay for a-mating factor activity: The strain MT502 was grown in 
YPD (1%o yeast extract, 2% peptone, 2% dextrose) to a density of 107 
cells/ml. 0.1 ml of cells was mixed with 4 ml of 0.7% YPD agar (at 
42°C) and spread on a YPD plate. After the agar had solidified, discs 
of filter paper (5 mm diameter) were placed on the top agar and 10 lal 
of peptide (1 mg/ml) was added to each disc. After incubation over- 
night the plates were inspected, and the diameter of the growth in- 
hibition zone was measured. 
Assay for binding to the LHRH receptor: Binding assays were 
performed as described by Millar et al. [17] using ~T3 gonadotrope 
cell membranes. Briefly, ceils were detached from the culture dishes in 
HEPES binding buffer (10 mM HEPES, 1 mM EDTA, pH 7.4), 
homogenized with a Dounce homogenizer and centrifuged at 
10000×g for 40 min at 4°C. The crude membrane pellet was resus- 
pended in binding buffer and incubated with approx. 50 000 cpm 2251- 
[D-Ala6,N-Me-LeuT,Prog-NHEt]-LHRH and 10 -5 M test peptide for 
60 min on ice to achieve quilibrium. The incubation was terminated 
by addition of 3 ml 0.01% aqueous polyethyleneimine and immediate 
filtration through glass-fiber filters (GF/C, Whatman) presoaked in 
1% polyethyleneimine. The filters were washed twice with 0.01%o poly- 
ethyleneimine and bound radioactivity was determined by scintillogra- 
phy. 
3. Results 
*Corresponding author. Fax: (45) 32683876. 
Tables 1 and 2 list the structures and amino acid analyses of 
the peptides ynthesized and tested for activity, while Fig. I 
shows representative mass spectrograms of commercial a -MF 
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and one of the hybrid peptides. All the hybrid peptides were 
purified by preparative HPLC after synthesis, and amino acid 
analyses were in agreement with the theoretically expected 
values. In Fig. 2 are shown the results of a -MF activity ex- 
periments. LHRH did not show ~-MF activity and neither 
did buserelin, an analogue of LHRH (Fig. 2A). A hybrid 
peptide, ~LHRH, consisting of the four C-terminal amino 
acids of ~-MF added to LHRH did not exhibit a -MF activity 
(Fig. 2B), and ~LHRH, furthermore, did not inhibit the bio- 
logical activity of a -MF in competition assays (Fig. 2C). 
Compared to a-MF, the c~LHRH hybrid molecule has the 
same C-terminal sequence (Pro-Gly-Gln-Pro-Met-Tyr) and 
identical residues at positions 2 and 3 (His-Trp). However, 
it has an N-terminal pGlu instead of Trp, an extra amino 
acid separating the His-Trp sequence from the C-terminal 
part of the molecule, a Tyr-Gly sequence instead of a Leu- 
Gin sequence in the middle of the molecule and arginine in- 
stead of lysine. Any one of these differences could account for 
the lack of ~-MF activity of c~LHRH and this was addressed 
by synthesis of further hybrid peptides (Table 1). An analogue 
of ~-MF, ~LHRH-1, in which Lys 7 was substituted with Arg 
exhibited full mating factor activity (Fig. 2D, Table 3). Thus, 
the conservative substitution does not impair the biological 
activity. The peptide c~LHRH-2 which contained an addi- 
tional change of the N-terminal Trp to pGlu also retained 
a -MF activity (Table 3). Consequently, the N-terminal charge 
and the Trp 1 side chain are unimportant for mating factor 
activity. A further change of Gin to Gly at position 5 relative 
to a -MF in the peptide aLHRH-3 also did not affect the 
mating factor activity (Fig. 2D, Table 3). This peptide differs 
from the inactive c~LHRH peptide only in the absence of Ser 4 
and in the conservative substitution of Leu for Tyr. Therefore, 
the insertion of Ser 4 of LHRH probably accounts for the 
inactivity of c~LHRH. Deletion of the C-terminal tetrapeptide 
(Gln-Pro-Met-Tyr) of ~LHRH-3 in ~LHRH-4 completely 
abolished mating factor activity (Fig. 2D, Table 3). 
Fig. 3 shows the results of receptor binding experiments. 
10 -5 M a-MF inhibited binding of the labelled LHRH ago- 
nist by 60.9% in membranes prepared from the e~T3 mouse 
gonadotroph cell line. This is in close agreement with the 
published IC~0 of 4.5 X 10 -5 M [3]. The other peptides howed 
less inhibition of LHRH agonist binding with no obvious 
correlation between structure and activity. ~LHRH and 
aLHRH-3 both showed around 50% inhibition of LHRH 
agonist binding, while c~LHRH-2 and aLHRH-4 both showed 
approx. 30% inhibition of agonist binding, aLHRH-1 was the 
least active peptide with no significant inhibition at the con- 
centration used. 
Table 1 
















To facilitate comparison a gap (- - -) has been introduced in some of 
the peptides. The three-letter abbreviations for the amino acids are 
used, pGlu denotes pyroglutamic acid and GlyNH2 denotes the C- 
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Fig. 1. Representative mass spectrograms of commercial ot-MF (A) 
and one of the hybrid peptides, aLHRH-3 (B), illustrating the pur- 
ity of the peptides used. 
Table 3 summarizes the results from the activity experi- 
ments. 
4. Discussion 
LHRH was found to be inactive in the ~-MF activity assay 
and a peptide consisting of the LHRH sequence plus a C- 
terminal extensioncorresponding to the C-terminus of a -MF 
was also inactive. This shows that the inactivity of LHRH was 
not solely due to the absence of the C-terminal residues of 
~-MF. Therefore, we made hybrid peptides consisting of ~-MF 
with progressively more amino acids characteristic of LHRH 
in order to assess which residues are necessary for a -MF 
activity and which residues of LHRH decrease ~-MF activity. 
Table 2 
Amino acid analysis of peptides used in this study and calculated 
and experimentally determined masses of the peptides 
~LHRH c~LHRH-1 ~LHRH-2 c~LHRH-3 c~LHRH-4 
Glu 1.5 (1) 2.3 (2) 3.4 (3) 2.2 (2) 1.2 (1) 
Pro 2.2 (2) 2.1 (2) 2.3 (2) 2.2 (2) 1.1 (1) 
Gly 1.9 (2) 1.5 (1) 1.1 (1) 2.2 (2) 2.2 (2) 
Met - 1.4 (1) 1.4 (1) 1.5 (1) - 
Leu 1.0 (1) 2.0 (2) 2.0 (2) 2.0 (2) 2.0 (2) 
Tyr 2.1 (2) 1.0 (1) 1.0 (1) 1.0 (1) - 
His 1.1 (1) 0.8 (1) 0.8 (1) 1.0 (1) 1.1 (1) 
Trp 0.8 (1) 1.6 (2) 1.6 (2) 1.0 (1) 0.7 (1) 
Arg 1.0 (1) 1.0 (1) 1.0 (1) 1.1 (1) 1.2 (1) 
Exp. mass 1703.3 1712.5 1638.3 1567.4 1047.0 
Calc. mass 1702.9 1712.0 1636.9 1565.9 1045.2 

















Fig. 2. Results of assay for ~-MF activity on yeast strain MT502. (A) Assay of tx-MF (a), LHRH (b) and buserelin (c). (B) Assay of o~-MF 
(a) and ctLHRH (b). (C) Competition assay between ct-MF and ctLHRH (1 mg/ml) in the following amounts: 10 t/1 (a), 5 ~tl (b), 1 ~tl (c), none 
(d). (D) a, ct-MF; b, LHRH; c, ctLHRH; d, ctLHRH-1; e, ctLHRH-2; f, ~tLHRH-3; g, ctLHRH-4. 
Previously, it was shown that Arg 8 is important for LHRH 
activity and that substitution with Lys decreased activity ap- 
prox. 10-fold [18]. We therefore investigated whether the re- 
verse applies to tx-MF. However, ctLHRH1 had tx-MF activ- 
ity, showing that either basic residue is tolerated in ct-MF. 
Additional substitution of Trp ~ with pGlu also did not affect 
ct-MF activity, in agreement with previous reports that Trp ~ is 
not important for a -MF  activity [19]. This is in contrast o 
LHRH where the N-terminal pGlu is important for activity 
[20]. Substitution of Gin ~ with the achiral Gly which is im- 
portant for LHRH activity [2l] did not affect ct-MF activity, 
Table 3 
Biological activities of the peptides tested in this study 
Peptide c~-MF activity LHRHR binding (% inhibition) 
LHRH - -  100 
o~-MF + 60.9 
~LHRH - -  46.4 
c~LHRH- 1 + 6.1 
ctLHRH-2 + 29.9 
~LHRH-3 + 47.8 
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Fig. 3. Histogram showing the results of testing the peptides for 
their ability to compete with an LHRH agonist for binding to the 
mammalian LHRH receptor. The figure shows the mean of tripli- 
cate determinations of LHRH agonist binding to the LHRH recep- 
tor in the absence (a) or presence of competing peptides (b-g). 
a, control; b, et-MF; c, ctLHRH; d, ctLHRH-1; e, ctLHRH-2; 
f, etLHRH-3; g, ctLHRH-4. 
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Table 4 
Structures of vertebrate LHRH molecules and yeast a-mating factors (cz-MF) 
165 
Peptide Sequence References 
Mammalian LHRH pEHWSYGLRPGNH2 [22,23] 
Chicken I LHRH pEHWSYGLQPGNH2 [24-27] 
Chicken II LHRH pEHWSHGWYPGNH2 [28] 
Salmon LHRH pEHWSYGWLPGNH2 [29] 
Catfish LHRH pEHWSHGLNPGNH2 [30] 
Dogfish LHRH pEHWSHGWLPGNH2 [31] 
Lamprey I LHRH pEHYSLGWKPGNH2 [32] 
Lamprey III LHRH pEHWSHDWKPGNH2 [33] 
Common for LHRH pEH S PG 
S. cerevisiae a-MF WHW-LQLKPGQPMY [19] 
S. klyuverii a-MF WHW-LSFSKGEPMY [34,35] 
Common for a-MF WHW-L  G PMY 
Common for active hybrid peptides and ot-MF HW-L  G PMY 
Common for all H G 
The one-letter abbreviations for the amino acids are used. 
indicating that neither the L-stereochemistry, nor the amide 
side chain is important for a -MF activity. Deletion of the 
C-terminal three residues of this peptide or insertion of a 
Ser in position 4 abolished a-MF activity. Together these 
two results confirm previous findings that the C-terminal res- 
idues of c~-MF are important for its activity [19] and show 
that the relative positions of the two ends of the molecule are 
important for activity. 
Analysis of the LHRH receptor binding activity of the hy- 
brid peptides did not support a functional relationship be- 
tween the two peptides. We replicated the previously reported 
LHRH receptor binding activity of a-MF. However, none of 
the hybrid peptides exhibited LHRH receptor binding activity 
intermediate between those of LHRH and cz-MF, and indeed 
all of the hybrid peptides were less active than cz-MF. 
A comparison of the structures of sexual hormones from 
different species (Table 4) points to a conserved role of the 
pGlul,His 2, Set 4, and Gly 1° for LHRH activity. In addition, 
position 3 is Trp in all LHRH variants except one where it is 
Tyr, and position 6 is Gly in all except one. Comparison of 
cz-mating factors and the active hybrid peptides hows con- 
servation of His 2, Trp 3, Leu 4, Gly °, Pro 11, Met 12, and Tyr 13. 
Thus, the only conserved amino acid in all the peptides listed 
in Table 2 is His 2 and this residue has been shown to be 
important for activity of both a -MF and LHRH [19,36,37]. 
However, the results presented here on the structure/activity 
relationships of c~-MF are significantly different from the re- 
ported structure/activity relationships of LHRH. Thus, there 
is very little conservation of function between the two peptides 
and the homology between the peptides may not reflect an 
evolutionary relationship. 
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